Harpoon Therapeutics To Present Interim Tolerability And Response Data From Phase 1/2 Clinical Trial Of T Cell Engager HPN328 At ESMO Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Harpoon Therapeutics is set to present interim tolerability and response data from the Phase 1/2 clinical trial of T cell engager HPN328 at the ESMO Congress 2023.
October 09, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Harpoon Therapeutics' upcoming presentation of interim data from the Phase 1/2 trial of HPN328 could potentially impact the company's stock.
The presentation of interim data from a clinical trial can often impact a biotech company's stock. Positive results could boost investor confidence, potentially leading to a rise in stock price, while negative results could have the opposite effect. However, without specific details on the data, the impact remains uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100